Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.

Olink Holding AB (publ)

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
 
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
 
For more information visit www.olink.com

Olink Proteomics

Touchdown in London! We're eager to discuss proteomics with you at the Festival of Genomics!

Swing by Booth #109 to discover how integrating genomics and proteomics helps reveal novel drug targets and new insights into disease pathways. Plus, don't miss your chance to see our Signature Q100 instrument in action!

We're looking forward to sharing ideas and learning together. Come and join the conversation!

#Olink #Proteomics #FOG2024



Will in-depth proteome profiling using self-sampled blood be the next step in monitoring individual health status in the era of precision medicine? Let’s hear the most recent progress in this topic from Professor Jochen M Schwenk (Royal Institute of Technology, Sweden) and discuss the challenges together in the session on Disease Proteomics at 29th Annual Lorne Proteomics Symposium on Feb 2, 2024, at Lorne, Australia!  

Check out the full symposium program at
https://bit.ly/3RMSubI 
#Proteomics #LorneProteomicsSymposium #Australia

We are thrilled to kick off the new year of events and connecting in person with you as our AMER team gears up for their first event of 2024 – PMWC (Precision Medicine World Conference)!
 
From our start, our mission has been to achieve the goal of precision medicine and individualized healthcare through the advancement of protein biomarker discovery and analysis. This future can only be realized with the collaboration of the scientific community so we are thrilled to connect with you at PMWC 2024 and the many events our teams will be attending. Stay tuned for updates as our team engages in insightful discussions and seeks to contribute to the future of healthcare.
 
Here's to a year filled with innovation, learning, and impactful connections! Let's make 2024 a year to remember! 🎉 

#PMWC2024 #precisionmedicine #olink

Extracting new insights from your genomics data? Discovering novel drug targets?
 
We're excited to share the power of proteomics with you at the Festival of Genomics & Biodata in London on Jan 24-25, 2024!
 
From biobank studies to disease-focused research, proteomics can empower your genomics projects and help you understand real-time human biology and overcome drug development challenges.
 
Come meet us at Booth #109 to discover how proteomics can complement your genomics studies and see our Signature Q100 instrument in action.
 
#Olink #Proteomics #FOG2024

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	2.06M -	6.66M 223.83%	8.67M 30.19%	6.88M 20.57%	18.76M 172.45%
accumulated other comprehensive income loss	2.60M -	39.36M 1,414.43%	1.70M 95.68%	-58.58M 3,543.92%	-42.30M 27.80%
cash and cash equivalents	6.16M -	8.65M 40.46%	118.10M 1,264.48%	75.11M 36.40%	120.96M 61.05%
cash and short term investments	6.16M -	8.65M 40.46%	118.10M 1,264.48%	75.11M 36.40%	120.96M 61.05%
common stock	22.12M -	27.22M 23.05%	30.96M 13.74%	30.99M 0.08%	32.22M 3.98%
deferred revenue	4.50M -	4.85M 7.64%	314K 93.52%	1.69M 439.49%	2.19M 29.40%
deferred revenue non current				-27.09M -
deferrred tax liabilities non current	30.34M -	33.19M 9.39%	27.09M 18.38%	22.20M 18.07%	21.30M 4.03%
goodwill	160.84M -	186.02M 15.65%	168.43M 9.46%	145.94M 13.35%	151.70M 3.94%
goodwill and intangible assets	302.40M -	347.39M 14.88%	308.12M 11.30%	257.48M 16.44%	258.68M 0.47%
intangible assets	141.56M -	161.37M 13.99%	139.69M 13.43%	111.53M 20.16%	106.99M 4.08%
inventory	11.89M -	20.83M 75.19%	28.94M 38.96%	44.25M 52.89%	66.44M 50.16%
long term debt	56.28M -	63.97M 13.66%	5.43M 91.52%	7.32M 34.92%	22.77M 210.91%
long term investments					1.79M -
net debt	94.25M -	57.46M 39.04%	-109.72M 290.96%	-65.67M 40.14%	-94.17M 43.39%
net receivables	17.76M -	36.34M 104.59%	46.16M 27.02%	63.09M 36.69%	66.24M 4.99%
other assets
other current assets	1.04M -	1.49M 42.68%	1K 99.93%		9.84M -
other current liabilities	3.64M -	14.81M 307.45%	19.65M 32.63%	25.39M 29.24%	30.51M 20.16%
other liabilities
other non current assets	127K -	133K 4.72%	422K 217.29%	571K 35.31%	6.48K 98.86%
other non current liabilities				27.09M -	571 100.00%
othertotal stockholders equity	199.12M -	257.77M 29.46%	506.01M 96.30%	514.13M 1.61%	620.23M 20.64%
preferred stock
property plant equipment net	7.52M -	10.46M 39.03%	21.47M 105.34%	24.95M 16.17%	57.03M 128.59%
retained earnings	-17.88M -	-24.66M 37.92%	-63.00M 155.48%	-75.86M 20.41%	-107.45M 41.65%
short term debt	44.13M -	2.15M 95.14%	2.95M 37.56%	2.11M 28.42%	4.02M 90.44%
short term investments
tax assets	10K -	37K 270%	9.09M 24,470.27%	10.85M 19.30%	21.29M 96.25%
tax payables	2.75M -	506K 81.61%	314K 37.94%	1.39M 342.36%	1.32M 4.97%
total assets	346.92M -	425.32M 22.60%	539.78M 26.91%	476.29M 11.76%	602.27M 26.45%
total current assets	36.86M -	67.31M 82.63%	200.67M 198.12%	182.45M 9.08%	263.47M 44.41%
total current liabilities	54.33M -	28.47M 47.60%	31.58M 10.95%	36.09M 14.26%	55.49M 53.76%
total debt	100.41M -	66.11M 34.16%	8.38M 87.33%	9.44M 12.60%	26.79M 183.94%
total investments					1.79M -
total liabilities	140.95M -	125.63M 10.87%	64.10M 48.97%	65.61M 2.34%	99.56M 51.75%
total liabilities and stockholders equity	346.92M -	425.32M 22.60%	539.78M 26.91%	476.29M 11.76%	602.27M 26.45%
total non current assets	310.06M -	358.01M 15.47%	339.11M 5.28%	293.84M 13.35%	338.79M 15.30%
total non current liabilities	86.62M -	97.16M 12.16%	32.52M 66.53%	29.52M 9.23%	44.07M 49.29%
total stockholders equity	205.97M -	299.70M 45.51%	475.68M 58.72%	410.69M 13.66%	502.71M 22.41%

COM:OLINK

Olink Holding AB

Last Close

26.00

09/07 20:00

Market Cap

3.24B

Beta: -

Volume Today

1.89M

Avg: -

Preview